Stifel Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst Paul Matteis initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $30.
Stifel analyst Paul Matteis initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $30.